What Amplo Biotechnology does

Amplo Biotechnology is a San Diego-based, privately held clinical-stage gene therapy company founded in 2021 that develops adeno-associated virus (AAV) therapies for diseases of the neuromuscular junction (NMJ). The company's pipeline centers on two candidates: AMP-101, an AAV-Dok7 therapy delivering the Dok-7 protein to treat Dok-7 Congenital Myasthenic Syndrome, and AMP-201, an AAV-Collagen-Q therapy expressing ColQ to treat ColQ Congenital Myasthenic Syndrome. Both candidates are built on Amplo's proprietary ASSET targeting platform, which is designed for muscle-targeted AAV delivery and is being applied initially to rare and ultra-rare patient populations.

Amplo's development strategy emphasizes capital efficiency and risk containment by using established AAV delivery technologies and manufacturing methods rather than novel platforms, concentrating development risk on indication selection. The company states it works with leading global NMJ experts and is dedicated exclusively to AAV therapies for the neuromuscular junction, with stated downstream ambitions into Emery-Dreyfuss Muscular Dystrophy, ALS, and ageing-related neuromuscular conditions. As of the most recent data, the lead candidate is at selection stage with an estimated 10-12 months remaining before clinical trial application.

The company is pre-revenue and does not yet have commercialized products or disclosed pricing. Its capital base consists of a 2021 Series Seed led by BioBrit, LLC with participation from Casdin Capital and SeedFolio (approximately $2.24M disclosed), non-dilutive NIH-NIAMS Fast Track Phase I/II STTR grant funding awarded in 2023, and a $2.89M award from the California Institute for Regenerative Medicine in early 2025. Go-to-market positioning targets rare disease channels, with future commercialization expected through specialty pharmacy and hospital-based distribution typical of rare disease gene therapies.

Name

Amplo Biotechnology

Legal name

Amplo Biotechnology

Website

https://amplobiotechnology.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Amplo Biotechnology is a San Diego-based private biotech developing AAV gene therapies (AMP-101 and AMP-201) targeting rare and ultra-rare neuromuscular junction disorders, including Congenital Myasthenic Syndromes.

Ownership category

akta.pro rank

Product category

Gene Therapy for Neuromuscular Junction Disorders

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

Neurology/CNS Gene Therapies (HLAAACAH), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• AAV gene therapy
• Neuromuscular junction disorders
• Congenital myasthenic syndromes
• Muscle-targeted therapy
• Rare disease therapeutics

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Gene Therapy Product Revenue: Pre-revenue biotech company developing gene therapy products for neuromuscular junction disorders. Expected to generate revenue through commercialization of AMP-101 and AMP-201 therapies upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Amplo Biotechnology develops muscle-targeted adeno-associated virus (AAV) gene therapies for diseases of the neuromuscular junction (NMJ). Its pipeline includes AMP-101 (AAV-Dok7) for Congenital Myasthenic Syndromes (CMS) and AMP-201 (AAV-Collagen-Q) for ColQ CMS, designed to deliver therapeutic proteins that address the genetic root causes of NMJ dysfunction. The company uses its proprietary ASSET targeting platform combined with established AAV delivery and manufacturing methods to pursue a capital-efficient development path for rare and ultra-rare patient populations.

Product overview

Amplo Biotechnology is a biotech company developing gene therapies for neuromuscular junction disorders. The company operates the ASSET platform for AAV-based gene therapy delivery. Their pipeline consists of two main gene therapy candidates: AMP-101 (AAV-Dok7 therapy targeting Dok-7 congenital myasthenic syndrome) and AMP-201 (AAV-Collagen-Q therapy targeting ColQ congenital myasthenic syndrome). The company uses known delivery technologies and manufacturing methods to reduce development risk while focusing capital efficiency on rare and ultra-rare patient populations.

Differentiator

Problem solved

Functional benefit

Products and services

• AMP-101 (AAV-Dok7) Muscle-targeted AAV gene therapy delivering the Dok-7 protein for the treatment of Congenital Myasthenic Syndromes (CMS), a group of genetic diseases of the neuromuscular junction. Dok-7 is central to the development and maintenance of the neuromuscular junction. Downstream applications include Emery-Dreyfuss Muscular Dystrophy, ALS, and ageing-related neuromuscular conditions. Intended for patients with Dok-7 CMS and related NMJ disorders.
• AMP-201 (AAV-Collagen-Q) AAV gene therapy based on targeted expression of the Collagen Q (ColQ) protein for the treatment of ColQ Congenital Myasthenic Syndrome. ColQ is critical for anchoring acetylcholinesterase at neuromuscular junction endplates and is essential for normal skeletal muscle function. Intended for patients with ColQ CMS caused by collagen Q deficiency.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Sarepta Therapeutics: Sarepta is a commercial-stage gene therapy leader for Duchenne muscular dystrophy (Elevidys AAV therapy) and other neuromuscular diseases. Comparable to Amplo because it targets muscle-based genetic diseases with AAV gene therapy, though it operates at vastly greater scale and broader indication set.
• Regenxbio: Regenxbio is an established AAV gene therapy platform company developing therapeutics for rare diseases including neuromuscular conditions. Comparable as it licenses/provides AAV delivery technology and develops its own pipeline, though it serves a much broader therapeutic portfolio than Amplo's NMJ focus.
• Voyager Therapeutics: Voyager develops AAV gene therapies for neurological diseases including ALS and Huntington's. Comparable for AAV platform approach and neuromuscular disease overlap (ALS), though Voyager is more advanced and broader in CNS scope.
• Astellas Gene Therapies (formerly Audentes): Astellas Gene Therapies develops AAV-based gene therapies including AT132 for X-linked myotubular myopathy, a severe neuromuscular disease. Directly comparable in AAV gene therapy approach and neuromuscular indication overlap, though operating as part of a major pharma.
• Pfizer (Bamboo Therapeutics / Gene Therapy Unit): Pfizer acquired Bamboo Therapeutics to build a neuromuscular gene therapy franchise (including DMD and LGMD programs) and continues to invest in this space. Comparable for neuromuscular AAV gene therapy focus, though at much greater scale and broader portfolio.

Direct peers

• Solid Biosciences: Solid Biosciences develops AAV gene therapies for Duchenne muscular dystrophy and other neuromuscular genetic diseases. Highly comparable to Amplo's muscle-targeted AAV approach, although at more advanced clinical stage and focused on DMD rather than NMJ biology.
• Genethon: Genethon is a French non-profit developing AAV gene therapies primarily for neuromuscular diseases including spinal muscular atrophy and Duchenne. Directly comparable as a neuromuscular-focused gene therapy developer with similar mission scope to Amplo's NMJ focus.

Emerging players

• Taysha Gene Therapies: Taysha is a clinical-stage gene therapy company targeting rare monogenic diseases of the CNS and peripheral nervous system using AAV. Comparable as an early-stage rare disease AAV company, though its CNS focus differs from Amplo's NMJ specialization.
• Kate Therapeutics: Kate Therapeutics is an early-stage gene therapy company focused on muscle and CNS diseases using novel AAV capsids. Comparable as a small emerging player developing muscle-targeted AAV therapies for genetic neuromuscular diseases, overlapping with Amplo's indication strategy.
• Lexeo Therapeutics: Lexeo Therapeutics develops AAV-based gene therapies for rare cardiac and neurological diseases from Weill Cornell. Comparable as a clinical-stage rare disease gene therapy company with platform-based approach, though focused more on cardiac and CNS indications than NMJ.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amplo-biotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amplo Biotechnology